Crescent Biopharma, Inc., a biotechnology company, researches and develops cancer therapy candidates in the United States. Its pipeline includes CR-001, which is in Phase 3 clinical trial, a proprietary anti-PD-1/anti-VEGF bispecific antibody to treat solid tumors; and CR-002, and CR-003. The company has a strategic partnership with Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. for the development and commercialization of oncology therapeutics. The company was formerly known as GlycoMimetics, Inc. The company was founded in 2024 and is headquartered in Waltham, Massachusetts.
Metrics to compare | CBIO | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship RelationshipCBIOPeersSector | |
|---|---|---|---|---|
P/E Ratio | −2.4x | −3.9x | −0.5x | |
PEG Ratio | −0.02 | −0.03 | 0.00 | |
Price/Book | 1.9x | 2.8x | 2.6x | |
Price / LTM Sales | 34.3x | 8.5x | 3.2x | |
Upside (Analyst Target) | 158.9% | 95.7% | 47.3% | |
Fair Value Upside | Unlock | −2.9% | 6.7% | Unlock |